All In Biotech

Drug Trial Radar · NCT03216486

An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta

A Phase 2, Non-controlled, Open-Label, Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta

Last checked: Nov 19, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Oct 31, 2017

Primary completion

Nov 1, 2018

Study completion Nov 1, 2018

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
Collaborators
Mereo BioPharma
First posted
Jul 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the effect of BPS804 on strength/quality of bone in patients with Type I, III or IV Osteogenesis imperfecta using a special type of CT scanner. Participants will be treated for 1 year.

Conditions

  • Osteogenesis Imperfecta

Interventions

  • BPS804Drug

    IV administration of BPS804 in 5% Dextrose solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in radial Trabecular Volumetric Bone Mineral Density (mgHA/cm3)Time frame: 12 months
  2. Change in radial bone strength on Finite Element Analysis (N)Time frame: 12 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Mereo Investigator Site

    Albuquerque, New Mexico

  • Mereo Investigator Site

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.